Posts Tagged: commercialization in Canada

Miroculus acquires Kapplex to advance diagnostics for complex diseases

Canadian innovation will give patients affordable, non-invasive, accurate test for cancer or infectious diseases; R&D team to remain in Toronto discovery district TORONTO and SAN FRANCISCO (May 3, 2016) — Miroculus, a San Francisco-based biotechnology company specializing in microRNA-based diagnostics, today announced an agreement to acquire Toronto-based Kapplex Inc. The Canadian company’s proprietary Digital Microfluidic (DMF) platform is built upon the research of Dr. Aaron Wheeler, a world-leader in microfluidics research at the University of Toronto. This announcement was covered in GenomeWeb and PeHub. When ... Read more

BioTuesdays features Xagenic and company’s molecular diagnostic beta trials

"Closely-held Xagenic plans to conduct beta studies this year, in advance of a major chlamydia and gonorrhea clinical trial, with its rapid X1 molecular diagnostic testing system in preparation for market launches in Europe and the U.S.," Leonard Zahr wrote in a feature article on Xagenic's product development progress for BioTuesdays on April 19, 2016. Xagenic was founded by University of Toronto Professor Shana Kelley in partnership with MaRS Innovation and U of T's Innovations & Partnerships Office in 2010. The company ... Read more

Triphase announces positive preclinical results for CBZed-Nano™

Results for results in docetaxel-resistant prostate cancer models presented at the American Association for Cancer Research (AACR) Conference TORONTO and SAN DIEGO (April 18, 2016) — Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, and the Ontario Institute for Cancer Research (OICR), today announced positive results from a preclinical study of their CBZed-Nano™ (cabazitaxel cellulose nanoparticle) product in docetaxel-resistant prostate cancer mouse models. Preliminary results also showed that the nanoparticles accumulate in intracranial brain ... Read more

XENiOS® invests $2.6 million in XOR-Labs Toronto

Partnership expected to revolutionize the supply of transplantable lungs, with market launch in Europe by XENiOS® expected in 2017 HEILBRONN, Germany and TORONTO, Canada — XENiOS®, a commercial-stage medical device company, announced today it has invested $2.6 million in XOR-Labs Toronto (“XOR”), a spin-off of Toronto General Hospital at University Health Network (UHN), the world’s leading center for lung transplantation, created in partnership with MaRS Innovation. This announcement was covered in FierceMedicalDevices and Cystic Fibrosis News Today. VICE featured XOR's life-saving lung transplant technology ... Read more

Accel-Rx and BDC Capital make second portfolio investment in ScarX Therapeutics

MaRS Innovation portfolio company completing Phase 1 human clinical trial of drug to prevent dermal scarring VANCOUVER (February 16, 2016) — Accel-Rx Health Sciences Accelerator (Accel-Rx), a Centre of Excellence for the Commercialization of Research (CECR), and its partner BDC Capital today announced their second joint investment in ScarX Therapeutics, a Canadian biotechnology company commercializing innovative treatments for dermal scarring (fibrosis). Accel-Rx and BDC Capital, and other investors including MaRS Innovation, have invested a total of $2 million in ScarX. This investment will ... Read more

Ontario advancing nine medical research projects in cancer, heart disease and sleep apnea to market

Applications for next MSc PoP granting round being accepted until February 25, 2016 TORONTO (January 26, 2016) — Nine Ontario-based medical research projects built on great science with potential for significant economic impact are advancing a step closer to market entry thanks to funding from Ontario Centres of Excellence’s Medical Sciences Proof-of-Principle (MSc PoP) program. The projects range from cancer to heart disease to sleep apnea in children. Applications for the next MSc PoP granting round are open until March 4, 2016. To ... Read more

Zucara Therapeutics Inc. developing drug to prevent hypoglycemic episodes for people with diabetes

TORONTO and VANCOUVER, CANADA (January 12, 2016) — A novel drug therapy to reduce the severity and frequency of hypoglycemic (low blood sugar) episodes in people with diabetes is being developed by Zucara Therapeutics Inc. This new start-up company, created by MaRS Innovation and The Centre for Drug Research and Development (CDRD) is based on decades of diabetes research by renowned University of Toronto (U of T) professor, Dr. Mladen Vranic. Zucara Therapeutics will attend Does of the Valley in February 2016. The ... Read more

Triphase secures FDA orphan drug designation for Marizomib in Malignant Glioma

TORONTO and SAN DIEGO (November 19, 2015) -- Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for marizomib to treat patients with malignant glioma. Malignant glioma is an aggressive form of brain cancer for which there is a significant unmet need in current treatments due to the disease's poor prognosis. Triphase is evaluating marizomib, a novel and highly ... Read more

Global University Venturing features MaRS Innovation’s unique model for technology transfer

MaRS Innovation's "model solves the two weakest points in tech transfer: the lack of dealflow and the ability to match public funding," writes Thierry Heles in, "MaRS Innovation: A Unique Model for Tech Transfer," for Global University Venturing. This feature was also covered in Techopia. The article, which includes an interview with Dr. Rafi Hofstein, president and CEO of MaRS Innovation, was published September 14, 2015. Here's an excerpt exploring the range of MI's portfolio and Hofstein's strategy for addressing technologies emerging in new ... Read more

Law firm partners with UTEST program to offer legal advice to early-stage startups

TORONTO, ON (August 10, 2015) — Toronto-based law firm Aird & Berlis LLP (A&B) has become the sponsoring legal partner to the University of Toronto Early-Stage Technology Program (UTEST). This partnership was covered in TechVibes, Law Times and the Financial Post's Legal Post blog. UTEST is a 12-month incubation and acceleration program co-managed by the University of Toronto (U of T) and MaRS Innovation that allows selected U of T-affiliated early-stage startup companies to incorporate, use office space, receive mentorship and access $30,000 ... Read more
Page 2 of 1212345...10...Last »